Saturday 17 October 2026
Export PBYI’s income statement to Excel — free account
Puma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.83
0.69
−6.56%
Follow PBYI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 8 | 7 | 7 |
| 39.69% | 27.97% | 21.62% | 21.97% | ||
| 17.46% | 14.48% | 12.54% | 13.78% | ||
ROIC |
39.95% | 43.78% | 51.10% | 42.61% | |
Return on Tangible Assets |
60.46% | 38.12% | 29.50% | 28.02% | |
Average Days of Receivables |
57.79 | 85.75 | 42.30 | 53.76 | |
Free Cash Flow per Share |
0.85 | 0.83 | 1.05 | 0.81 | |
Free Cash Flow |
42.87 | 41.73 | 53.61 | 41.15 | |
Capital Expenditures |
(0.12) | (0.07) | — | — | |
| Other line items | |||||
Cash ROIC |
17.46% | 16.53% | 22.03% | 17.70% | |
Accounts Receivable Turnover |
4.81 | 5.33 | 8.82 | 7.71 | |
Accounts Payable Turnover |
7.05 | 11.01 | 8.18 | 13.65 | |
Inventory Turnover |
8.06 | 8.17 | 6.65 | 5.31 | |
Average Days of Payables |
47.62 | 31.73 | 51.37 | 19.47 | |
Days of Inventory on Hand |
70.66 | 34.61 | 54.68 | 83.56 | |
Tax Rate |
0.20 | (0.13) | (0.16) | (0.14) | |
Research and Development Expense of Revenue |
28.49% | 27.18% | 29.93% | 30.90% | |
Selling, General and Administrative Expense of Revenue |
32.59% | 31.02% | 31.55% | 30.78% | |
Share Based Compensation of Revenue |
3.34% | 3.04% | 3.00% | 3.09% | |
Interest Coverage |
4.13 | 5.63 | 5.70 | 8.65 | |
Operating CF/Net income |
1.16 | 1.34 | 2.20 | 1.54 | |
Depreciation/Fixed assets |
36.47 | 58.49 | 86.50 | 101.74 | |
Capex/Depreciation |
(0.01) | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
4.21 | 4.57 | 4.47 | 4.54 | |
Operating CF per Share |
0.85 | 0.84 | 1.05 | 0.81 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates